All studies
Critical care · Claims · US
Garry 2022
COVID-19
ITT, ATSuperiorityIndustry, Government0/5 disclosures
Comparisons
2
In the analysis
2
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments
Design and methods
- Estimand
- ITT, AT
- Design hypothesis
- Superiority
- Matching / weighting
- 1:1 PS matching, IPTW
- Analysis method
- Cox PH
- Missing data
- NR
- Covariates adjusted
- 6
- DAG
- No
- QBA
- No
Data and sample
- Data type
- Claims
- Data sources
- 1
- Geography
- US
- Treated
- 8812
- Control
- 8812
- Emulations
- 1
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Not declared
- Funding
- Not declared
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2022_Gary_COVID_ConferenceAbstract
- DOI
- https://dx.doi.org/10.1002/pds.5518
- Affiliations
- Aetion Inc, US Food and Drug Administration, HealthVerity
- Sector
- Industry, Government
- Target trials (study level)
- RECOVERY
- Registration
- NCT04381936